Randomized controlled trial of the lipid-lowering therapy with rosuvastatin and atorvastatin for the patients with coronary artery disease treated with percutaneous coronary intervention

Randomized controlled trial of the lipid-lowering therapy with rosuvastatin and atorvastatin for the patients with coronary artery disease treated with percutaneous coronary intervention - Randomized controlled trial of the lipid-lowering therapy with rosuvastatin and atorvastatin for the patients with coronary artery disease treated with percutaneous coronary intervention

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014342

Enrollment

300

Registered

2014-07-01

Start date

2013-11-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

Distribution to rosuvastatin 5mg/day for 9 months Distribution to atorvastatin 10mg/day for 9 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Coronary artery disease patinets treated with percutaneous coronary intervention (2) Patients with LDL-cholesterol>100mg/dl

Exclusion criteria

Exclusion criteria: (1)Patients who developed acute myocardial infarction within 30days from percutaneous coronary intervention (2)Patinets who had been treated with percutaneous coronary intervention (3)Patients treated with fibrate-based medicine (4)Patients treated with hemodyalysis (5)Patients diagnosed with familial hypercholesterolemia (6)Patients who developed stroke within 3 months from percutaneous coronary intervention (7)Patients having liver damage (8)Patients having renal damage (9)Patients having high level of serum creatine phosphokinase (10)Patients treated with cyclosporin (11)Pregnant patients (12)Patients with hypothyroidism or muscular disorder (13)Drug abuse and alcoholic patients (14)Patients having carcinoma (15)Patients having severe complications (16)Patients having allergy of rosuvastatin or atorvastatin

Design outcomes

Primary

Measure	Time frame
Major adverse cardiac events cardiovascular death non-fatal acute coronary syndrome non-fatal stroke target vascular revascularization	—

Secondary

Measure	Time frame
admission by congestive heart failure etc.	—

Countries

Japan

Contacts

Public ContactYokoyama Hiroaki

Hirosaki University Graduate School of Medicine Cardiology

hero8686@cc.hirosaki-u.ac.jp0172-39-5057

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026